Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker-Reference-Cited by-同舟云学术

Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker

Published:2024-06 Issue:6 Volume:300 Page:107325
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Zamani Mohammad Reza,Hadzima Martin^ORCID,Blažková Kristýna,Šubr Vladimír,Ormsby Tereza,Celis-Gutierrez Javier,Malissen Bernard^ORCID,Kostka Libor,Etrych Tomáš,Šácha Pavel^ORCID,Konvalinka Jan

Funder

Grantová Agentura, Univerzita Karlova

Grantová Agentura České Republiky

National Cancer Research Institute

European Commission

Ministry of Education Youth and Sports of the Czech Republic

Publisher

Elsevier BV

Reference59 articles.

1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat. Rev. Cancer,2012

2. Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis;Huang;J. Cancer,2021

3. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome;Alsaab;Front Pharmacol.,2017

4. Recent findings in the regulation of programmed death ligand 1 expression;Shen;Front. Immunol.,2019

5. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells;Latchman;Proc. Natl. Acad. Sci. U. S. A.,2004

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Antibody Therapies in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28